RECRUITING

Analysis of Red Blood Cell Integrity and Efficiency of Recovery Using a Novel Surgical Sponge-Blood Recovery Device (ProCell): Immediate Impact

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this research study is to compare two methods of recovering blood from surgical sponges used during heart and lung surgeries. The two methods are: 1) manually wringing sponges by hand, and 2) automated wringing sponges by an FDA approved suction device. Both methods are already in use in heart and lung surgeries at University Hospitals at the discretion of the surgeon.

Official Title

Analysis of Red Blood Cell Integrity and Efficiency of Recovery Using a Novel Surgical Sponge-Blood Recovery Device (ProCell): Immediate Impact

Quick Facts

Study Start:2022-09-20
Study Completion:2025-02-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05545930

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 89 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Undergoing heart or lung transplant, redo sternotomy, aortic surgery, and/or multi-valve repairs/replacements; and
  2. * At University Hospitals Cleveland Medical Center.
  1. * Patients with known bleeding disorders, including disseminated intravascular coagulation (DIC), prothrombin deficiency, factor V deficiency, factor VII deficiency, factor X deficiency, factor XI deficiency (hemophilia C), Glanzmann disease, hemophilia A, hemophilia B, idiopathic thrombocytopenic purpura (ITP), and Von Willebrand disease (types I, II, and III);
  2. * Patients undergoing emergent or emergent salvage surgery; and
  3. * Patients actively participating in another clinical trial which could affect outcomes.

Contacts and Locations

Study Contact

Craig Jarrett, MD, MBA
CONTACT
216-286-7297
Craig.Jarrett@UHhospitals.org

Principal Investigator

Marc Pelletier, MD
PRINCIPAL_INVESTIGATOR
University Hospitals Cleveland Medical Center
Craig Jarrett, MD, MBA
PRINCIPAL_INVESTIGATOR
University Hospitals Cleveland Medical Center

Study Locations (Sites)

University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106
United States

Collaborators and Investigators

Sponsor: Marc Pelletier

  • Marc Pelletier, MD, PRINCIPAL_INVESTIGATOR, University Hospitals Cleveland Medical Center
  • Craig Jarrett, MD, MBA, PRINCIPAL_INVESTIGATOR, University Hospitals Cleveland Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-09-20
Study Completion Date2025-02-01

Study Record Updates

Study Start Date2022-09-20
Study Completion Date2025-02-01

Terms related to this study

Keywords Provided by Researchers

  • Open Heart Surgery
  • Heart Transplant
  • Lung Transplant
  • ProCell

Additional Relevant MeSH Terms

  • Blood Recovery